Cognito Therapeutics & Aetion Partner On Model To Identify Risk Of Decline From Mild Cognitive Impairment To Alzheimer’s Disease

Cognito Therapeutics, a pioneer in therapeutic interventions for neurodegenerative diseases and Aetion, a global real-world evidence (RWE) technology and analytics provider, are in partnership to develop a validated predictive model aimed at identifying consumers with rapidly progressing mild cognitive impairment (MCI) and Alzheimer’s disease. This first-in-class predictive model would accelerate clinical development for Cognito’s late-stage clinical program in mild-to-moderate MCI and Alzheimer’s disease by identifying consumers who may benefit from treatment earlier. Cognito will launch a multi-study, late-stage clinical program evaluating its disease-modifying optogenetics-based therapeutic in consumers . . .